Cullinan Therapeutics, Inc.
CGEMHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeCullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. At a $1.36B market cap, Cullinan Therapeutics, Inc. ranks as a small-cap company within healthcare. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Market Cap
$1.36B
Beta
0.02
P/E (TTM)
—
P/E (Fwd)
-8.15
EPS (TTM)
$-3.10
EPS (Fwd)
$-2.71
ROE
-50.3%
ROA
-31.4%
Cash
$334.5M
Total Debt
$2.1M
Free CF
-$89.2M
52W Change
217.0%
Annual Financials
Cash vs Debt
Where CGEM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CGEM finished 41.87% above its 150-day moving average ($15.74) and 54.11% above its 200-day moving average ($14.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGEM overbought or oversold?
At the September 3, 2026 close, CGEM's RSI(14) was 66.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $334.5M in cash and $2.1M in debt, CGEM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$89.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -50.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.02 suggests CGEM is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cullinan Therapeutics, Inc. and its sector.